Ruzurgi®
Amifampridine tablets

On May 31st 2021, the notice of compliance (NOC) for Ruzurgi® was suspended in furtherance to a Federal Court decision pertaining to data protection provisions. Thus, sales of Ruzurgi® are suspended pending a redetermination by Health Canada. Medunik is working diligently with all parties involved to ensure minimal disruption for patients. This situation is not related to the safety nor efficacy of the product.
Patient Support Program

Medunik Canada, in collaboration with Innomar Strategies, is proud to offer a complete Patient Support Program for Ruzurgi®. The Unik Access Program provides individualized and confidential support for the excellent care that Neurologic Centres offer their patients.

The highlights of this program are as follows:

  • Reimbursement navigation
    • Assistance in applications and coordination of benefits
    • Financial assistance
  • Specialty pharmacy services
    • Patient drug counselling
    • Personalized distribution channel (pharmacy or home)
    • Solution preparation counselling and support, when necessary
  • Patient follow-ups conducted by a nurse
    • Education
    • Adherence and compliance

Your physician can easily enroll you in the Unik Access Program by completing the enrolment form and by forwarding it to Innomar Strategies by fax at 1-855-756-7661 or e-mail at This email address is being protected from spambots. You need JavaScript enabled to view it.. Innomar will make all required follow-ups with you and/or your health care professional.

To find out more about the Unik Access Program, please contact Innomar Strategies directly at 1-855-756-7660. For more information about Ruzurgi®, please contact Médunik Canada’s Medical Information team at 1-855-633-8645 or at This email address is being protected from spambots. You need JavaScript enabled to view it..